HR and breast cancer: In locally advanced breast cancer (LABC), multivariate analysis indicated that 48% of patients with the overexpression of HER2 (treated with NAC plus Trastuzumab ± Pertuzumab) achieved pCR versus 7% of patients with the HR+/HER2− subtype, or 23% of TN patients; both of the latter groups were only treated with NAC (p < 0.001) [13].